Search

Your search keyword '"Massaro, Fulvio"' showing total 35 results
Start Over Author "Massaro, Fulvio" Search Limiters Full Text
35 results on '"Massaro, Fulvio"'

1. Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.

Author

Massaro, Fulvio, Andreozzi, Fabio, Abrassart, Tom, Castiaux, Julie, Massa, Hanne, Rizzo, Ornella, and Vercruyssen, Marie

Subjects
LYMPHOPROLIFERATIVE disorders, BISPECIFIC antibodies, HODGKIN'S disease, CHIMERIC antigen receptors, HEMATOLOGIC malignancies
Abstract

Over the past three decades, the treatment of lymphoproliferative disorders has undergone profound changes, notably due to the increasing availability of innovative therapies with the potential to redefine clinical management paradigms. A major impact is related to the development of monoclonal antibodies, checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T (CAR-T) cell therapies. This review discusses the current landscape of clinical trials targeting various hematological malignancies, highlighting promising early-phase results and strategies to overcome resistance. Lymphoproliferative disorders encompass a range of conditions: while in Hodgkin lymphoma (HL) the goal is to reduce chemotherapy-related toxicity by integrating immunotherapy into the frontline setting, peripheral T cell lymphoma (PTCL) lacks effective targeted therapies. The review emphasizes a shifting therapeutic landscape towards precision medicine and treatment modalities that are less toxic yet more effective. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. HIGHLIGHTS FROM THE 20TH IWCLL

Author

Massaro, Fulvio, De Wilde, Virginie, Massaro, Fulvio, and De Wilde, Virginie

Abstract

info:eu-repo/semantics/published

Published
2023

7. New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy

Author

Andreozzi, Fabio, Massaro, Fulvio, Wittnebel, Sebastian, Spilleboudt, Chloé, Lewalle, Philippe, Salaroli, Adriano, Andreozzi, Fabio, Massaro, Fulvio, Wittnebel, Sebastian, Spilleboudt, Chloé, Lewalle, Philippe, and Salaroli, Adriano

Abstract

For decades, intensive chemotherapy (IC) has been considered the best therapeutic option for treating acute myeloid leukemia (AML), with no curative option available for patients who are not eligible for IC or who have had failed IC. Over the last few years, several new drugs have enriched the therapeutic arsenal of AML treatment for both fit and unfit patients, raising new opportunities but also new challenges. These include the already approved venetoclax, the IDH1/2 inhibitors enasidenib and ivosidenib, gemtuzumab ozogamicin, the liposomal daunorubicin/cytarabine formulation CPX-351, and oral azacitidine. Venetoclax, an anti BCL2- inhibitor, in combination with hypomethylating agents (HMAs), has markedly improved the management of unfit and elderly patients from the perspective of improved quality of life and better survival. Venetoclax is currently under investigation in combination with other old and new drugs in early phase trials. Recently developed drugs with different mechanisms of action and new technologies that have already been investigated in other settings (BiTE and CAR-T cells) are currently being explored in AML, and ongoing trials should determine promising agents, more synergic combinations, and better treatment strategies. Access to new drugs and inclusion in clinical trials should be strongly encouraged to provide scientific evidence and to define the future standard of treatment in AML., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2022

8. Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis

Author

Massaro, Fulvio, Meuleman, Nathalie, Bron, Dominique, Vercruyssen, Marie, Maerevoet, Marie, Massaro, Fulvio, Meuleman, Nathalie, Bron, Dominique, Vercruyssen, Marie, and Maerevoet, Marie

Abstract

Classical Hodgkin lymphoma (HL) patients presenting a relapsed/refractory (R/R) disease are currently managed with salvage chemotherapy followed by autologous stem cell transplantation (ASCT). However, almost 25–30% of these patients fail to achieve a complete response (CR) with standard salvage regimens. In this retrospective study, we evaluated the efficacy of a combination of brentuximab vedotin (BV) and pembrolizumab in a series of HL patients presenting with a high-risk, multi-refractory disease. Patients achieving a Deauville score ≤4 proceeded to ASCT consolidation. After ASCT, patients received BV as maintenance for a total of 16 administrations. We collected data from 10 patients with a median age of 30.7 years. At a median follow-up of 16.5 months, we reported a complete metabolic remission (CMR) in eight patients (80%), with seven patients (70%) directly proceeding to ASCT (the other two patients in CMR are still undergoing treatment). BV consolidation was started in six patients and completed by three patients (one ongoing, two interruption). Two patients (20%) presented a progressive disease (PD) and subsequently died, while the others are still in CMR. The BV and pembrolizumab combination is a very effective bridge treatment to ASCT for high-risk R/R HL patients., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2022

12. Prognostic Impact of Muscle Quantity and Quality and Fat Distribution in Diffuse Large B-Cell Lymphoma Patients

Author

Besutti, Giulia, primary, Massaro, Fulvio, additional, Bonelli, Efrem, additional, Braglia, Luca, additional, Casali, Massimiliano, additional, Versari, Annibale, additional, Ligabue, Guido, additional, Pattacini, Pierpaolo, additional, Cavuto, Silvio, additional, Merlo, Domenico F., additional, Luminari, Stefano, additional, Merli, Francesco, additional, Vaccaro, Salvatore, additional, and Pellegrini, Massimo, additional

Published
2021
Full Text
View/download PDF

13. Aging of bone marrow mesenchymal stromal cells: Hematopoiesis disturbances and potential role in the development of hematologic cancers

Author

Massaro, Fulvio, Corrillon, Florent, Stamatopoulos, Basile, Meuleman, Nathalie, Lagneaux, Laurence, Bron, Dominique, Massaro, Fulvio, Corrillon, Florent, Stamatopoulos, Basile, Meuleman, Nathalie, Lagneaux, Laurence, and Bron, Dominique

Abstract

Aging of bone marrow is a complex process that is involved in the development of many diseases, including hematologic cancers. The results obtained in this field of research, year after year, underline the important role of cross-talk between hematopoietic stem cells and their close environment. In bone marrow, mesenchymal stromal cells (MSCs) are a major player in cell-to-cell communication, presenting a wide range of functionalities, sometimes opposite, depending on the environmental conditions. Although these cells are actively studied for their therapeutic properties, their role in tumor progression remains unclear. One of the reasons for this is that the aging of MSCs has a direct impact on their behavior and on hematopoiesis. In addition, tumor progression is accompanied by dynamic remodeling of the bone marrow niche that may interfere with MSC functions. The present review presents the main features of MSC senescence in bone marrow and their implications in hematologic cancer progression., SCOPUS: re.j, info:eu-repo/semantics/published

Published
2021

14. Hodgkin's lymphoma: post- autologous transplantation consolidation therapy

Author

Merli, Francesco, Ballerini, Filippo, Botto, Barbara, Gotti, Manuel, Pavone, Vincenzo, Pulsoni, Alessandro, Stefani, Pietro Maria, Massaro, Fulvio, and Viviani, Simonetta

Subjects
Adult, post-autologous trasplantation, How I Treat, Hodgkin Disease, Transplantation, Autologous, Consolidation Chemotherapy, Young Adult, Humans, Female, Neoplasm Recurrence, Local, Hodgkin lymphoma, autologous stem cell transplant, consolidation therapy, Stem Cell Transplantation
Abstract

A first-line chemotherapy program based on the ABVD regimen is currently considered the golden standard by most hematologists, being able to achieve a cure without any need of subsequent therapies in >70% of patients with advanced-stage Hodgkin’s lymphoma (HL). To increase this percentage, efforts in recent decades focused on the development of new therapeutic strategies. A first major effort was the introduction of the BEACOPP chemotherapy regimen, which is able to increase the response rate and to reduce the need of salvage therapies. However, this result did not demonstrate an advantage in terms of overall survival compared to ABVD, mainly due to an excess of non lymphoma-related events in the follow-up phase. Here we describe three clinical cases of young HL patients who had relapsed/refractory disease after the induction chemotherapy. These three clinical cases provide practical and real world evidence in favor of the use of BV in monotherapy as consolidation treatment after autologous stem cells transplantation in patients with relapsed/refractory HL.

Published
2020

16. Management of Extramedullary Intradural Spinal Tumors: The Impact of Clinical Status, Intraoperative Neurophysiological Monitoring and Surgical Approach on Outcomes in a 12-Year Double-Center Experience

Author

Cofano, Fabio, primary, Giambra, Carlotta, additional, Costa, Paolo, additional, Zeppa, Pietro, additional, Bianconi, Andrea, additional, Mammi, Marco, additional, Monticelli, Matteo, additional, Di Perna, Giuseppe, additional, Junemann, Carola Vera, additional, Melcarne, Antonio, additional, Massaro, Fulvio, additional, Ducati, Alessandro, additional, Tartara, Fulvio, additional, Zenga, Francesco, additional, and Garbossa, Diego, additional

Published
2020
Full Text
View/download PDF

20. Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?

Author

De Benedittis, Daniela, primary, Breccia, Massimo, additional, Carmosino, Ida, additional, Mariggiò, Elena, additional, Molica, Matteo, additional, Mohamed, Sara, additional, Massaro, Fulvio, additional, De Luca, Maria Lucia, additional, Scalzulli, Emilia, additional, Lisi, Chiara, additional, Passucci, Mauro, additional, Colafigli, Gioia, additional, Loglisci, Maria Giovanna, additional, Diverio, Daniela, additional, Mancini, Marco, additional, Foà, Robin, additional, and Latagliata, Roberto, additional

Published
2018
Full Text
View/download PDF

25. Incidence of Severe (≤ 10g/dl) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy

Author

Cesini, Laura, primary, Carmosino, Ida, additional, Campanelli, Melissa, additional, Breccia, Massimo, additional, De Luca, Maria Lucia, additional, Colafigli, Gioia, additional, Molica, Matteo, additional, Massaro, Fulvio, additional, Vozella, Federico, additional, Diverio, Daniela, additional, Mancini, Marco, additional, Alimena, Giuliana, additional, and Latagliata, Roberto, additional

Published
2016
Full Text
View/download PDF

26. Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis

Author

Breccia, Massimo, primary, Tiribelli, Mario, additional, Bonifacio, Massimiliano, additional, Tieghi, Alessia, additional, Polverelli, Nicola, additional, Bergamaschi, Micaela, additional, Cavazzini, Francesco, additional, Cimino, Giuseppe, additional, D'Adda, Mariella, additional, Crugnola, Monica, additional, Bosi, Costanza, additional, Spinsanti, Marco, additional, Molica, Matteo, additional, Fama, Angelo, additional, Andriani, Alessandro, additional, Cerqui, Elisa, additional, Lazzaro, Antonio, additional, Scaffidi, Luigi, additional, Massaro, Fulvio, additional, Latagliata, Roberto, additional, Celesti, Francesca, additional, Lemoli, Roberto massimo, additional, Fanin, Renato, additional, Russo, Domenico, additional, Aversa, Franco, additional, Cuneo, Antonio, additional, Cavo, Michele, additional, Vianelli, Nicola, additional, Alimena, Giuliana, additional, and Palandri, Francesca, additional

Published
2016
Full Text
View/download PDF

28. Unusual Bulky Presentation due to Missed Diagnosis of Hodgkin Lymphoma

Author

Martelli Maurizio, Massaro Fulvio, Molica Matteo, Perrone Salvatore, Foà Robin, and Capria Saveria

Subjects
medicine.medical_specialty, business.industry, Lymphoma diagnosis, Large-cell lymphoma, Medicine, Hodgkin lymphoma, Missed diagnosis, Presentation (obstetrics), business, Omics, Bioinformatics, medicine.disease, Dermatology
Published
2015

33. Does Bone Marrow Fibrosis Play a Role in the Prognostication of Newly Diagnosed Polycythemia Vera Patients?

Author

Molica, Matteo, De Benedictis, Daniela, Scalzulli, Emilia, Carmosino, Ida, Cesini, Laura, Chisini, Marta, De Luca, Maria Lucia, Massaro, Fulvio, Colafigli, Gioia, Mancini, Marco, Trasarti, Stefania, Breccia, Massimo, Foa, Robin, and Latagliata, Roberto

Abstract

According to the WHO 2016 revised classification of myeloproliferative disorders, bone marrow biopsy is included among the major criteria for the diagnosis of policythemia vera (PV). However, the prognostic role of marrow fibrosis at baseline in PV patients is still controversial and, to date, there are few data in the literature focusing on this issue. We retrospectively analyzed the histologic features at diagnosis of 279 patients affected by PV managed at our Institution from 01/1982 to 05/2014 and with an available bone marrow analysis. Patients' characteristics at diagnosis were: male/female 146/133 (52.3%/47.7%), median age 58.2 years [interquartile range (IQR) 48.8-66.6], median Hb 18.2 g/dl (IQR 17.1-19.7), median WBC 10.5 x 109/l (IQR 8.3-13.9), median PLTs 501 x 109/l (IQR 343-711) and median JAK2-V617F allele burden 57.4% (IQR 18.1-86.1). Furthermore, 115 (41.2%) patients presented an enlarged spleen at diagnosis and 45 (16.1%) reported a thrombotic episode prior to diagnosis. According to the histologic bone marrow findings at diagnosis, 196 (70.2%) patients presented a bone marrow fibrosis grade 0, while 83 (29.7%) had a grade >0 fibrosis (grade I-II). The baseline features of the two subsets of patients were compared (Table 1): a significant difference was observed only with regard to the Ht value (p=0.031) and the PLT value (p=0.036). After a median follow-up of 136 months (IQR 67.5-213.7), the two groups were compared in terms of thrombotic episodes developed during the follow-up [56/279 patients (20%)], evolution into a myelofibrotic phase (MF) [41/279 patients (14.6%)], evolution into a blastic phase (BP) [21/279 patients (7.5%)] and overall survival (OS). The subset of patients with a marrow fibrosis >0 showed a trend towards significance for a reduced occurrence of thrombotic episodes during the follow-up [10/83 (12%) vs 46/196 (23.4%), p=0.096). We did not find any statistical difference between the two groups considering the rate of evolution into MF [9/83 (10.8%) vs 32/196 (16.3%), p=0.23], the rate of evolution into BP [4/83 (4.8%) vs 17/196 (6%), p=0.23) and the median OS (110.7 vs 113.5 months, p=0.771). According to our data, the presence of a bone marrow fibrosis at baseline in PV patients was associated only to a trend towards a decreased risk of developing thrombotic events and did not influence the follow-up and prognosis. Taken together, these data do not confirm the prognostic impact of bone marrow fibrosis in PV and suggest that further prospective evaluations are warranted to conclusively clarify this controversial issue.

Published
2017
Full Text
View/download PDF

34. Hodgkin's lymphoma: post- autologous transplantation consolidation therapy.

Author

Merli F, Ballerini F, Botto B, Gotti M, Pavone V, Pulsoni A, Stefani PM, Massaro F, and Viviani S

Subjects
Adult, Consolidation Chemotherapy, Female, Humans, Neoplasm Recurrence, Local therapy, Transplantation, Autologous, Young Adult, Hodgkin Disease drug therapy, Hodgkin Disease surgery, Stem Cell Transplantation
Abstract

A first-line chemotherapy program based on the ABVD regimen is currently considered the golden standard by most hematologists, being able to achieve a cure without any need of subsequent therapies in >70% of patients with advanced-stage Hodgkin's lymphoma (HL). To increase this percentage, efforts in recent decades focused on the development of new therapeutic strategies. A first major effort was the introduction of the BEACOPP chemotherapy regimen, which is able to increase the response rate and to reduce the need of salvage therapies. However, this result did not demonstrate an advantage in terms of overall survival compared to ABVD, mainly due to an excess of non lymphoma-related events in the follow-up phase. Here we describe three clinical cases of young HL patients who had relapsed/refractory disease after the induction chemotherapy. These three clinical cases provide practical and real world evidence in favor of the use of BV in monotherapy as consolidation treatment after autologous stem cells transplantation in patients with relapsed/refractory HL.

Published
2020
Full Text
View/download PDF

35. Early and late complications related to central venous catheters in hematological malignancies: a retrospective analysis of 1102 patients.

Author

Morano SG, Coppola L, Latagliata R, Berneschi P, Chistolini A, Micozzi A, Girmenia C, Breccia M, Brunetti G, Massaro F, Rosa G, Guerrisi P, Mandelli F, Foà R, and Alimena G

Abstract

Several severe complications may be associated with the use of central venous catheters (CVC). We retrospectively evaluated on a large cohort of patients the incidence of CVC-related early and late complications. From 7/99 to 12/2005, 1102 CVC have been implanted at our Institution in 881 patients with hematological malignancies (142,202 total day number of implanted CVC). Early mechanic complications were 79 (7.2% - 0.55/1,000 days/CVC). Thirty-nine episodes of early infective complications (<1 week from CVC implant) occurred (3.5% - 0.3/1000 days/CVC): furthermore, 187 episodes of CVC-related sepsis (17% - 1.3/1000 days/CVC) were recorded. There were 29 episodes (2.6%) of symptomatic CVC-related thrombotic complications, with a median interval from CVC implant of 60 days (range 7 - 395). The rate of CVC withdrawal due to CVC-related complications was 26%. The incidence of CVC-related complications in our series is in the range reported in the literature notwithstanding cytopenia often coexisting in hematological patients.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results